{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:22:14Z","timestamp":1792624934073,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["R01AI169781"],"award-info":[{"award-number":["R01AI169781"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01220-y","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:38:35Z","timestamp":1753457915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of a bivalent protein subunit vaccine against infection by Pseudomonas aeruginosa and Staphylococcus aureus"],"prefix":"10.1038","volume":"10","author":[{"given":"Suhrid","family":"Maiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prolay","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debaki Ranjan","family":"Howlader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zackary K.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satabdi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Shafiullah","family":"Parvej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mst. Nusrat","family":"Zahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean K.","family":"Whittier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Picking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy L.","family":"Picking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"1220_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.706157","volume":"12","author":"DR Howlader","year":"2021","unstructured":"Howlader, D. R. et al. Effect of two unique nanoparticle formulations on the efficacy of a broadly protective vaccine against Pseudomonas aeruginosa. Front. Pharm. 12, 706157 (2021).","journal-title":"Front. Pharm."},{"key":"1220_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad265","volume":"10","author":"D Ince","year":"2023","unstructured":"Ince, D. et al. Epidemiology of gram-negative bloodstream infections in the United States: results from a cohort of 24 hospitals. Open Forum Infect. Dis. 10, ofad265 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"1220_CR3","unstructured":"WHO Bacterial Priority Pathogens List 2024 : Bacterial Pathogens of Public Health Importance, to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance. 1st edn, (World Health Organization, 2024)."},{"key":"1220_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4161\/hv.34296","volume":"11","author":"K Grimwood","year":"2015","unstructured":"Grimwood, K., Kyd, J. M., Owen, S. J., Massa, H. M. & Cripps, A. W. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum. Vaccin Immunother. 11, 14\u201320 (2015).","journal-title":"Hum. Vaccin Immunother."},{"key":"1220_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jcf.2021.09.015","volume":"21","author":"F Ratjen","year":"2022","unstructured":"Ratjen, F. & VanDevanter, D. R. Retracing changes in cystic fibrosis understanding and management over the past twenty years. J. Cyst. Fibros. 21, 3\u20139 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"1220_CR6","unstructured":"Bagnoli, F., Rappuoli, R. Grandi, G. in Current Topics in Microbiology and Immunology Vol. 409 (ed R. Rappuoli) 540 (Springer International Publishing, 2017)."},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","volume":"22","author":"WR Miller","year":"2024","unstructured":"Miller, W. R. & Arias, C. A. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat. Rev. Microbiol 22, 598\u2013616 (2024).","journal-title":"Nat. Rev. Microbiol"},{"key":"1220_CR8","doi-asserted-by":"crossref","unstructured":"Parsons, J. B., Westgeest, A. C., Conlon, B. P. & Fowler, V. G., Jr. Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Host, Pathogen, and Treatment. Antibiotics 12,12030455 (2023).","DOI":"10.3390\/antibiotics12030455"},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/s-0039-1698464","volume":"40","author":"AC Blanchard","year":"2019","unstructured":"Blanchard, A. C. & Waters, V. J. Microbiology of cystic fibrosis airway disease. Semin Respir. Crit. Care Med. 40, 727\u2013736 (2019).","journal-title":"Semin Respir. Crit. Care Med."},{"key":"1220_CR10","doi-asserted-by":"crossref","unstructured":"Killough, M., Rodgers, A. M. & Ingram, R. J. Pseudomonas aeruginosa: recent advances in vaccine development. Vaccines 10, 10071100 (2022).","DOI":"10.3390\/vaccines10071100"},{"key":"1220_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.xphs.2017.02.024","volume":"106","author":"V Iyer","year":"2017","unstructured":"Iyer, V. et al. Feasibility of freeze-drying oil-in-water emulsion adjuvants and subunit proteins to enable single-vial vaccine drug products. J. Pharm. Sci. 106, 1490\u20131498 (2017).","journal-title":"J. Pharm. Sci."},{"key":"1220_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583008","volume":"11","author":"S Das","year":"2020","unstructured":"Das, S. et al. Development of a broadly protective, self-adjuvanting subunit vaccine to prevent infections by Pseudomonas aeruginosa. Front Immunol. 11, 583008 (2020).","journal-title":"Front Immunol."},{"key":"1220_CR13","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1128\/IAI.00181-12","volume":"80","author":"EB Norton","year":"2012","unstructured":"Norton, E. B., Lawson, L. B., Mahdi, Z., Freytag, L. C. & Clements, J. D. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect. Immun. 80, 2426\u20132435 (2012).","journal-title":"Infect. Immun."},{"key":"1220_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/sur.2018.233","volume":"19","author":"C Merakou","year":"2018","unstructured":"Merakou, C., Schaefers, M. M. & Priebe, G. P. Progress toward the elusive Pseudomonas aeruginosa vaccine. Surg. Infect.19, 757\u2013768 (2018).","journal-title":"Surg. Infect."},{"key":"1220_CR15","doi-asserted-by":"crossref","unstructured":"Sainz-Mejias, M., Jurado-Martin, I. & McClean, S. Understanding Pseudomonas aeruginosa-host interactions: the ongoing quest for an efficacious vaccine. Cells 9, 9122617 (2020).","DOI":"10.3390\/cells9122617"},{"key":"1220_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fimmu.2018.00431","volume":"9","author":"B Corthesy","year":"2018","unstructured":"Corthesy, B. & Bioley, G. Lipid-based particles: versatile delivery systems for mucosal vaccination against infection. Front. Immunol. 9, 431 (2018).","journal-title":"Front. Immunol."},{"key":"1220_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4155\/tde-2016-0068","volume":"8","author":"N Marasini","year":"2017","unstructured":"Marasini, N., Skwarczynski, M. & Toth, I. Intranasal delivery of nanoparticle-based vaccines. Ther. Deliv. 8, 151\u2013167 (2017).","journal-title":"Ther. Deliv."},{"key":"1220_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/eji.201142346","volume":"42","author":"PE Makidon","year":"2012","unstructured":"Makidon, P. E. et al. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur. J. Immunol. 42, 2073\u20132086 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1220_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijpharm.2017.07.012","volume":"530","author":"B Bernocchi","year":"2017","unstructured":"Bernocchi, B., Carpentier, R. & Betbeder, D. Nasal nanovaccines. Int J. Pharm. 530, 128\u2013138 (2017).","journal-title":"Int J. Pharm."},{"key":"1220_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00618-w","volume":"8","author":"DR Howlader","year":"2023","unstructured":"Howlader, D. R. et al. A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection. NPJ Vaccines 8, 37 (2023).","journal-title":"NPJ Vaccines"},{"key":"1220_CR21","doi-asserted-by":"crossref","unstructured":"Reboud, E., Basso, P., Maillard, A. P., Huber, P. & Attree, I. Exolysin shapes the virulence of Pseudomonas aeruginosa clonal outliers. Toxins 9, 9110364 (2017).","DOI":"10.3390\/toxins9110364"},{"key":"1220_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1372349","volume":"15","author":"DR Howlader","year":"2024","unstructured":"Howlader, D. R. et al. Development of a nano-emulsion based multivalent protein subunit vaccine against Pseudomonas aeruginosa. Front Immunol. 15, 1372349 (2024).","journal-title":"Front Immunol."},{"key":"1220_CR23","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1021\/bi200369p","volume":"50","author":"CF Gaudin","year":"2011","unstructured":"Gaudin, C. F., Grigg, J. C., Arrieta, A. L. & Murphy, M. E. Unique heme-iron coordination by the hemoglobin receptor IsdB of Staphylococcus aureus. Biochemistry 50, 5443\u20135452 (2011).","journal-title":"Biochemistry"},{"key":"1220_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcimb.2012.00016","volume":"2","author":"F Bagnoli","year":"2012","unstructured":"Bagnoli, F., Bertholet, S. & Grandi, G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front. Cell Infect. Microbiol. 2, 16 (2012).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1220_CR25","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.4161\/hv.34407","volume":"10","author":"TB McNeely","year":"2014","unstructured":"McNeely, T. B. et al. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum. Vaccin Immunother. 10, 3513\u20133516 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"1220_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.chom.2022.06.006","volume":"30","author":"CM Tsai","year":"2022","unstructured":"Tsai, C. M. et al. Non-protective immune imprint underlies failure of Staphylococcus aureus IsdB vaccine. Cell Host microbe 30, 1163\u20131172 e1166 (2022).","journal-title":"Cell Host microbe"},{"key":"1220_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14760584.2023.2179486","volume":"22","author":"CM Tsai","year":"2023","unstructured":"Tsai, C. M., Caldera, J., Hajam, I. A. & Liu, G. Y. Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step? Expert Rev. Vaccines 22, 207\u2013209 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"1220_CR28","doi-asserted-by":"crossref","unstructured":"Le, H. N. et al. MEDI3902 correlates of protection against severe pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model. Antimicrob. Agents Chemother. 62, 02517 (2018).","DOI":"10.1128\/AAC.02565-17"},{"key":"1220_CR29","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1128\/AAC.01213-16","volume":"60","author":"BA Diep","year":"2016","unstructured":"Diep, B. A. et al. Improved protection in a rabbit model of community-associated methicillin-resistant staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin. Antimicrob. Agents Chemother. 60, 6333\u20136340 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1220_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/21645515.2019.1650999","volume":"16","author":"SM Baker","year":"2020","unstructured":"Baker, S. M., McLachlan, J. B. & Morici, L. A. Immunological considerations in the development of Pseudomonas aeruginosa vaccines. Hum. Vaccin Immunother. 16, 412\u2013418 (2020).","journal-title":"Hum. Vaccin Immunother."},{"key":"1220_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2174\/138920312804871210","volume":"13","author":"M Galle","year":"2012","unstructured":"Galle, M., Carpentier, I. & Beyaert, R. Structure and function of the type III secretion system of Pseudomonas aeruginosa. Curr. Protein Pept. Sci. 13, 831\u2013842 (2012).","journal-title":"Curr. Protein Pept. Sci."},{"key":"1220_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mib.2008.12.007","volume":"12","author":"J Engel","year":"2009","unstructured":"Engel, J. & Balachandran, P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr. Opin. Microbiol 12, 61\u201366 (2009).","journal-title":"Curr. Opin. Microbiol"},{"key":"1220_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","volume":"67","author":"V Irani","year":"2015","unstructured":"Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol. Immunol. 67, 171\u2013182 (2015).","journal-title":"Mol. Immunol."},{"key":"1220_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/j.1699-0463.1999.tb01514.x","volume":"107","author":"C Moser","year":"1999","unstructured":"Moser, C. et al. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS 107, 1093\u20131100 (1999).","journal-title":"APMIS"},{"key":"1220_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00281-011-0291-7","volume":"34","author":"D Parker","year":"2012","unstructured":"Parker, D. & Prince, A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol. 34, 281\u2013297 (2012).","journal-title":"Semin Immunopathol."},{"key":"1220_CR36","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1080\/21645515.2019.1613126","volume":"15","author":"A Ferraro","year":"2019","unstructured":"Ferraro, A. et al. Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus. Hum. Vaccin Immunother. 15, 2980\u20132992 (2019).","journal-title":"Hum. Vaccin Immunother."},{"key":"1220_CR37","doi-asserted-by":"crossref","unstructured":"Muntaka, S. et al. Gamma Interferon and Interleukin-17A Differentially Influence the Response of Human Macrophages and Neutrophils to Pseudomonas aeruginosa Infection. Infect. Immun. 87, 814 (2019).","DOI":"10.1128\/IAI.00814-18"},{"key":"1220_CR38","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2353\/ajpath.2008.080337","volume":"173","author":"M von Kockritz-Blickwede","year":"2008","unstructured":"von Kockritz-Blickwede, M. et al. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am. J. Pathol. 173, 1657\u20131668 (2008).","journal-title":"Am. J. Pathol."},{"key":"1220_CR39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3389\/fimmu.2020.01160","volume":"11","author":"JF Alcorn","year":"2020","unstructured":"Alcorn, J. F. IL-22 Plays A Critical Role In Maintaining Epithelial Integrity During Pulmonary Infection. Front. Immunol. 11, 1160 (2020).","journal-title":"Front. Immunol."},{"key":"1220_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/ni.2025","volume":"12","author":"GF Sonnenberg","year":"2011","unstructured":"Sonnenberg, G. F., Fouser, L. A. & Artis, D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383\u2013390 (2011).","journal-title":"Nat. Immunol."},{"key":"1220_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2018.04.001","volume":"41","author":"P Rozman","year":"2018","unstructured":"Rozman, P. & Svajger, U. The tolerogenic role of IFN-gamma. Cytokine Growth Factor Rev. 41, 40\u201353 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1220_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","volume":"21","author":"K Wolk","year":"2004","unstructured":"Wolk, K. IL-22 increases the innate immunity of tissues. Immunity 21, 241\u201354 (2004).","journal-title":"Immunity"},{"key":"1220_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek, T. R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153\u201365 (2010).","journal-title":"Immunity"},{"key":"1220_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou, L. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol 8, 967\u201374 (2007).","journal-title":"Nat. Immunol"},{"key":"1220_CR45","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","volume":"1843","author":"MD Turner","year":"2014","unstructured":"Turner, M. D., Nedjai, B., Hurst, T. & Pennington, D. J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochimica et. Biophysica Acta (BBA) - Mol. Cell Res. 1843, 2563\u20132582 (2014).","journal-title":"Biochimica et. Biophysica Acta (BBA) - Mol. Cell Res."},{"key":"1220_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"J Bradley","year":"2008","unstructured":"Bradley, J. TNF-mediated inflammatory disease. J. Pathol. 214, 149\u2013160 (2008).","journal-title":"J. Pathol."},{"key":"1220_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/21645515.2018.1527496","volume":"15","author":"R Billeskov","year":"2019","unstructured":"Billeskov, R., Babak, B. & Berzofsky, J. A. The effect of antigen dose on T cell-targeting vaccine outcome. Hum. Vaccines Immunother. 15, 407\u2013411 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"1220_CR48","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1086\/657156","volume":"202","author":"KL Strandberg","year":"2010","unstructured":"Strandberg, K. L. et al. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J. Infect. Dis. 202, 1690\u20131697 (2010).","journal-title":"J. Infect. Dis."},{"key":"1220_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1258\/002367771781006483","volume":"5","author":"PN O\u2019Donoghue","year":"1971","unstructured":"O\u2019Donoghue, P. N. & Whatley, B. F. Pseudomonas aeruginosa in rabbit fur. Lab Anim. 5, 251\u2013255 (1971).","journal-title":"Lab Anim."},{"key":"1220_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1297281","volume":"13","author":"E Gras","year":"2023","unstructured":"Gras, E. et al. Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development. Front. Cell Infect. Microbiol. 13, 1297281 (2023).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1220_CR51","doi-asserted-by":"publisher","first-page":"357ra124","DOI":"10.1126\/scitranslmed.aag1153","volume":"8","author":"BA Diep","year":"2016","unstructured":"Diep, B. A. et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci. Transl. Med. 8, 357ra124\u2013357ra124 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1220_CR52","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1073\/pnas.0912403107","volume":"107","author":"BA Diep","year":"2010","unstructured":"Diep, B. A. et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl. Acad. Sci. USA 107, 5587\u20135592 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01220-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T01:32:49Z","timestamp":1757295169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01220-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01220-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WLP and WDP are founders and part owners of Hafion, Inc. The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}